Nesiritide

Summary

Nesiritide (Natrecor) is a recombinant form of human BNP approved for the intravenous treatment of acutely decompensated congestive heart failure with dyspnea at rest or minimal activity. It produces balanced arterial and venous vasodilation and promotes diuresis and natriuresis.

Mechanism of Action

Nesiritide binds the natriuretic peptide receptor‑A (NPR‑A), a membrane guanylyl cyclase. Activation of NPR‑A stimulates intracellular cyclic GMP production, which relaxes vascular smooth muscle, dilates arteries and veins, promotes natriuresis, and inhibits renin‑angiotensin‑aldosterone activity. The combined preload‑reducing and afterload‑reducing effects improve cardiac filling pressures and pulmonary congestion.

What the Research Shows

Reviews of intensive‑care practice cite nesiritide as a newer vasodilator option for cardiogenic pulmonary edema, but note that larger trials are still needed. The ROSE‑AHF trial, a double‑blind, placebo‑controlled study, examined low‑dose nesiritide as a renal adjunct in acute heart failure with renal dysfunction; results were mixed and did not establish clear renoprotective benefit. More recent ESC statements highlight that contemporary meta‑analyses and two recent trials failed to demonstrate survival advantage, leading to a downgrade of vasodilator use in acute heart failure guidelines. Overall, evidence supports hemodynamic effects but lacks consistent outcome benefit.

Reported Benefits

Evidence indicates that nesiritide can lower left‑ventricular filling pressures, improve pulmonary edema, and produce balanced arterial‑venous vasodilation, which may be useful in acute decompensated heart failure. Small studies suggest possible renal function preservation when used at low doses, though the ROSE‑AHF findings were inconclusive. Its rapid intravenous action makes it attractive for emergent hemodynamic stabilization.

Limitations of the Evidence

Clinical trials have not demonstrated mortality or long‑term outcome benefits, and recent guideline updates have downgraded its routine use. The ROSE‑AHF study yielded conflicting renal‑protective results, and meta‑analyses have not shown consistent superiority over standard therapies. Consequently, nesiritide remains a niche option rather than a standard of care.

Safety Considerations

Recent literature raises concerns about the safety and overall effectiveness of nesiritide. Hypotension is a recognized adverse effect due to its vasodilatory action, and some studies have questioned its net clinical benefit. No specific severe adverse events are detailed in the provided abstracts, but the overall safety profile remains under scrutiny.

How It Is Administered

Nesiritide is administered intravenously, typically as an infusion in acute care settings such as emergency departments or intensive‑care units. The formulation is a recombinant peptide prepared for sterile infusion. Dosing regimens vary by study and clinical protocol, but the drug is delivered only under medical supervision.

Routes of Administration

Goals & Uses

• Reduction of preload and afterloadHemodynamicHigh
• Natriuresis and diuresisFluid/electrolyte ManagementModerate
• Relief of dyspnea in acutely decompensated heart failureCardiovascularHigh
• Reduction of BNP/neurohormonal activationNeurohormonalModerate
• Acute decompensated heart failure symptom reliefCardiovascularModerate

Contraindications

• Hypersensitivity to nesiritide or any componentAllergyHigh
• Systolic blood pressure < 90 mmHgHemodynamicHigh
• Cardiogenic shockCardiovascularHigh
• Low cardiac filling pressureHemodynamicHigh
• Recent myocardial infarction (≤30 days)CardiovascularModerate
• Severe hypotensionCardiovascularHigh

Adverse Effects

• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularCommonLow blood pressure
• Renal dysfunctionRenalUncommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Back painMusculoskeletalUncommonPain in the back
• BradycardiaCardiovascularRare
• Worsening renal functionRenalUncommon

Drug Interactions

• Other vasodilators (e.g., nitroglycerin, hydralazine)Moderate
• Antihypertensives (e.g., ACE inhibitors, ARBs, calcium channel blockers)Moderate
• Vasodilators (e.g., nitrates, hydralazine)Moderate
• DiureticsModerateMay worsen dehydration or electrolyte imbalance

Population Constraints

• Pregnancy (Category C)ReproductiveRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative
• Pregnant womenReproductiveRelative
• Patients with systolic BP < 90 mmHgCardiovascularAbsolute

Regulatory Status

• European UnionUnapprovedNever received marketing authorization.
• United StatesWithdrawnIndication withdrawn 2015; product discontinued 2017.
• United KingdomUnapprovedNot licensed.

FDA approved 2001; indication for acute decompensated heart failure withdrawn 2015; commercial discontinuation 2017. Not approved in EU or UK.

Evidence & Sources

• Cardiogenic pulmonary edema: mechanisms and treatment - an intensivist's view
  Journal ArticleModerateIngbar DH2019-01-01T00:00:00.000000Z
• ROSE-AHF and lessons learned
  Journal ArticleModerateJain AK, Chen HH2014-01-01T00:00:00.000000Z
• Shock - Classification and Pathophysiological Principles of Therapeutics
  Journal ArticleModerateKislitsina ON, et al.2019-01-01T00:00:00.000000Z
• Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
  Journal ArticleModerateChioncel O, et al.2025-01-01T00:00:00.000000Z
• Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications
  Journal ArticleModeratePotter LR, et al.2009-01-01T00:00:00.000000Z

Frequently Asked Questions